J&J, Sinopharm, Sputnik V shots weaker against Omicron, study shows | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
June 14, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, JUNE 14, 2025
J&J, Sinopharm, Sputnik V shots weaker against Omicron, study shows

Coronavirus chronicle

Reuters
17 December, 2021, 07:25 pm
Last modified: 17 December, 2021, 08:33 pm

Related News

  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women
  • Study on Bangladeshi children confirms lasting impact of typhoid vaccine

J&J, Sinopharm, Sputnik V shots weaker against Omicron, study shows

Reuters
17 December, 2021, 07:25 pm
Last modified: 17 December, 2021, 08:33 pm
J&J, Sinopharm, Sputnik V shots weaker against Omicron, study shows

Covid-19 vaccines from US drugmaker Johnson & Johnson and China's Sinopharm as well as Russia's Sputnik V shot had no neutralizing activity against the Omicron variant, according to a study which has not yet been peer reviewed.

The Omicron variant has raised concerns regarding its ability to evade protection provided by widely-used vaccines, with drugmakers tailoring their shots to target the variant while testing the effectiveness of their existing shots.

Vaccines from Moderna, AstraZeneca and Pfizer and partner BioNTech retained activity against Omicron, but the antibody response was greatly reduced when compared with the original virus strain first detected in China, the study found.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The study, conducted by Humabs Biomed SA, a unit of Vir Biotechnology and the University of Washington, among others, also found the decrease was less pronounced for vaccinated individuals who were previously infected.

The study also found that while the effectiveness of GlaxoSmithKline  and Vir Biotech's Covid-19 drug sotrovimab reduced three-fold against Omicron compared to the original strain, monoclonal antibody treatments by Regeneron and Eli Lilly completely lost their neutralizing activity against the variant.

The finding is consistent with recent laboratory tests demonstrating the two treatments lose most of their effectiveness when exposed to the Omicron variant.

In a real-world study published this week, it was seen that Pfizer-BioNTech's Covid-19 vaccine has been less effective in South Africa at keeping people infected with the virus out of hospital since the Omicron variant emerged last month.

Top News / World+Biz

Omicron Covid variant / Vaccine / J&J Covid-19 Vaccine / Sinopharm Covid-19 Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Infograph: TBS
    Lowering targets and missing those: Is splitting NBR enough to break the cycle?
  • Missiles launched from Iran are intercepted as seen from Tel Aviv. REUTERS/Jamal Awad
    Iran fires missiles at Israel in response to attacks; Trump says it's not too late for nuclear deal
  • Infographic: TBS
    Govt plans incentives for Bangladeshis bringing in foreign investment

MOST VIEWED

  • Energy adviser Fouzul Kabir Khan with other government officials during a visit to Sylhet gas field on 13 June 2025. Photo: TBS
    I would disconnect gas supply to every home in Dhaka if I could: Energy adviser
  • BNP Acting Chairperson Tarique Rahman and Chief Adviser  Muhammad Yunus meet at Dorchester Hotel in London, UK on 13 June 2025. Photo: CA Press Wing
    National polls possible in 2nd week of February, agree Yunus, Tarique in 'historic' London meeting
  • Rescuers work at the scene of a damaged building in the aftermath of Israeli strikes, in Tehran, Iran, June 13, 2025. Majid Asgaripour/WANA (West Asia News Agency) via REUTERS
    Tehran retaliates with 100 drones after Israel strikes Iran's nuclear facilities, kills military leaders
  • From fact-checker to fact-checked: CA Press Wing’s turn in the hot seat
    From fact-checker to fact-checked: CA Press Wing’s turn in the hot seat
  • UK Prime Minister Keir Starmer, Chief Adviser Muhammad Yunus
    Disclosure of unconfirmed Yunus-Starmer meeting shows ‘diplomatic imprudence’: Analysts
  • Flight AI 379 had landed. File Photo: Hindustan Times
    Day after Ahmedabad crash, Air India flight makes emergency landing in Thailand after bomb threat

Related News

  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women
  • Study on Bangladeshi children confirms lasting impact of typhoid vaccine

Features

Photos: Collected

Kurtis that make a great office wear

16h | Mode
Among pet birds in the country, lovebirds are the most common, and they are also the most numerous in the haat. Photo: Junayet Rashel

Where feathers meet fortune: How a small pigeon stall became Dhaka’s premiere bird market

2d | Panorama
Illustration: Duniya Jahan/ TBS

Forget Katy Perry, here’s Bangladesh’s Ruthba Yasmin shooting for the moon

3d | Features
File photo of Eid holidaymakers returning to the capital from their country homes/Rajib Dhar

Dhaka: The city we never want to return to, but always do

4d | Features

More Videos from TBS

No Cash in ATMs: System Glitch or Something Deeper?

No Cash in ATMs: System Glitch or Something Deeper?

10h | TBS Today
Iran-Israel military power; who is ahead?

Iran-Israel military power; who is ahead?

12h | TBS World
Did the possibility of an Iran nuclear deal set back after the attack?

Did the possibility of an Iran nuclear deal set back after the attack?

13h | TBS World
IRGC chief Major General Hossein Salami killed in Israeli strike

IRGC chief Major General Hossein Salami killed in Israeli strike

15h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net